© Copyright 2025 | RDiscovery | All Rights Reserved
© Copyright 2025 | RDiscovery | All Rights Reserved
At Sanodyne Therapeutics, we are dedicated to bringing hope and relief to patients from peripheral neuropathy and neuropathic pan. By leveraging cutting-edge science and our deep experience in pain management, we are committed to developing innovative therapies that restore comfort and improve quality of life.
Capacity Bio is a private, Los Angeles-based biotech company developing a first-in-class mitophagy therapeutic platform, along with the most advanced analytical toolkit to characterize mitochondria. The team has discovered a novel cellular target that induces mitochondrial turnover, resulting in improved mitochondrial quality. Capacity’s pipeline includes opportunities in neurodegenerative and autoimmune disorders, myopathies, and genetic orphan indications.
We are a venture capital led drug discovery startup focusing on the concept of “Sensory Medicine”.
Sensory Medicine is a concept that integrates and induces the latent bioprotective abilities of humans and animals through sensory stimulation.
Our groundbreaking work has pioneered the development of pharmaceutical seeds that induce artificial hibernation based on this “Sensory Medicine” concept. This innovation offers new therapeutic options for patients grappling with emergency diseases and underscores our commitment to spearheading global healthcare innovations.
The term “Myrodia” is derived from the Greek word “scent”.
Viage Therapeutics, a neuroscience company based on a platform of novel neurotherapeutics, was founded in 2018. The company is based on the ground-breaking research of Dr. Kousaku Ohinata from Kyoto University.
DGX-001, Viage’s clinical drug candidate, represents a first-in-class oral drug candidate targeting the gut-brain axis. The proposed mechanism of action of DGX-001 is to modulate the vagus nerve through specific receptor interactions on enteroendocrine cells in the gut, resulting in a regulation of brain cell activity.
DGX-001 is in clinical development and was well-tolerated in a healthy volunteer Phase 1 study, consistent with its positive safety profile in preclinical GLP studies. In the clinical study, DGX-001 increased specific brain activity (EEG measures) and a post hoc analysis indicated improvements in cognition based on Cogstate tests. Furthermore, human PK measurements have so far been undetectable systemically, confirming the preclinical finding the drug candidate is gut-restricted and gut-acting, which may further minimize off-target side effects as majority of PD patients suffer from comorbidities and polypharmacy.
The Company is headquartered in the San Francisco Bay Area.
